$PSID In order to fully capitalize on this strong industry growth, companies like PSID will have to create scalable technologies that will not only set them apart from their competitors but also set higher barriers to entry for potential competitors. PositiveID is hard at work doing just that. They recently finished the design of the second-phase prototype of the Firefly Dx product. Firefly DX is a real-time, mobile polymerase chain reaction (PCR) pathogen detection system, which means that it is a rapid medical testing device that is highly effective, portable, and much faster than traditional diagnostic methods. Firefly was developed for the $27 billion dollar commercial diagnostics market, wherein PSID has made agreements with entities such as NASA, ENSCO, and USSOCOM. Furthermore the company recently reported its first revenues since the business launched, showing that the company is gaining a foothold in the industry and has overcome many of the initial startup hurdles faced by biosensor companies. Having gained entry into this blooming market early is a great step for the company, as they will be positioned to reap the rewards from the major industry-wide growth in the near future.
